Shield Therapeutics (LON:STX)‘s stock had its “corporate” rating restated by equities research analysts at FinnCap in a research note issued to investors on Wednesday, ThisIsMoney.Co.Uk reports.
STX has been the subject of a number of other reports. Peel Hunt restated a “buy” rating and set a GBX 200 ($2.61) price objective on shares of Shield Therapeutics in a research report on Wednesday, October 2nd. Peel Hunt restated a “buy” rating on shares of Shield Therapeutics in a research report on Tuesday.
Shares of STX stock opened at GBX 185.50 ($2.42) on Wednesday. The business’s 50-day moving average price is GBX 182.76 and its 200-day moving average price is GBX 130.61. Shield Therapeutics has a 12 month low of GBX 30 ($0.39) and a 12 month high of GBX 202 ($2.64). The firm has a market capitalization of $217.39 million and a price-to-earnings ratio of 51.53. The company has a current ratio of 4.79, a quick ratio of 4.57 and a debt-to-equity ratio of 0.26.
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Further Reading: Rule of 72
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.